Treatment With Subcutaneous Drainage in the Pneumomediastinum and Massive Subcutaneous Emphysema

Dear Editor,

Pneumomediastinum (PM) and subcutaneous emphysema (SE) are generally benign entities with a self-limiting course. There is a potential risk for complications due to massive accumulation of air that could compromise the life of the patient by interfering with respiratory mechanics and complicating venous return. In these cases, a less aggressive and effective therapeutic option is the use of subcutaneous drains. We present the case of a 75-year-old male with PM and massive SE that was resolved with this type of drains.

A 75-year-old male with GOLD grade IV COPD, who had undergone upper right lobectomy for pulmonary epidermoid carcinoma, came to our emergency room due to COPD exacerbation. The patient was admitted to hospital and evolved favorably during the first 72 h. On the fourth day of hospitalization, after the exertion of defecating, he presented dyspnea and left pleuritic chest pain. Upon examination, subcutaneous emphysema was found in the apical region of the left hemithorax. Chest radiography confirmed the presence of air in the subcutaneous tissue. The patient was treated with rest, oxygen therapy and analgesia, but the subcutaneous emphysema extended throughout the thorax, face, eyelids and abdomen. Thoracic CT showed the presence of PM and massive SE with no evidence of pneumothorax, pulmonary emphysema and post-surgical absence of the left upper pulmonary lobe (Fig. 1). After 48 h, the patient presented symptoms of thoracic discomfort, sweating and presyncope, and electrocardiogram demonstrated paroxysmal atrial fibrillation. In this situation, it was decided to insert a right subcutaneous drain (Fig. 2). The patient’s symptoms improved almost immediately, and the drain was able to be withdrawn 5 days later. Over the following 6 months, the patient presented no relapse.

PM and SE are usually caused by a iatrogenic or traumatic trigger, although on occasion they may be secondary to an abrupt increase in intra-alveolar pressure, which is a phenomenon known as the Macklin effect.1 The incidence of PM is low although underdiagnosed because its symptoms are non-specific and the radiological signs are difficult to identify. Typical symptoms at onset include chest pain, dyspnea and subcutaneous emphysema, and occasionally cervical pain, odynophagia, dysphagia, dysphonia

Fig. 1. (A and B) Thoracic CT image showing the presence of gas in the subcutaneous and mediastinal tissue.
Infections by Gram-Negative Bacilli in Patients With Pulmonary Arterial Hypertension Treated With Intravenous Prostacyclin

Infecciones por gramnegativos en pacientes con hipertensión arterial pulmonar tratados con prostaciclinas intravenosas

Dear Editor,

I have read with great interest the original article by López Medrano et al.1 regarding the high incidence of bacteremia due to Gram-negative bacteria (GNB) in patients with pulmonary arterial hypertension (PAH) treated with intravenous (IV) treprostinil compared with IV epoprostenol. This is a known finding in the literature and has been confirmed in a Spanish center with extensive experience in the management of PAH. They also suggest initial empirical therapeutic management until the pathogen is correctly identified. In their conclusions, the authors invite us to carefully weigh the risks and benefits of treatment with IV treprostinil.

Recently, Kitterman et al.2 have published data about the incidence of bloodstream infection in 1146 patients with PAH from the REVEAL Registry in the United States. They had been treated with either IV epoprostenol or treprostinil, and a greater incidence of infection due to GNB was found in the IV treprostinil group (0.20 vs 0.03 per 1000 days of treatment, P<.001). However, this US series shows that the rate of infection has dropped drastically in recent years since the publication and approval of the Clinical Practice Guidelines for the prevention of bacteremia due to central venous catheter in the treatment of PAH with prostanooids.3 Our own center had also experienced a reduction in the rates of infection in recent years since guidelines were adopted.

Fig. 2. Posteroanterior and lateral chest radiography showing massive accumulation of air in the subcutaneous tissue. The proximal end of the subcutaneous drain can be observed in the third right intercostal space (arrows).

References


Mariluz Santalla Martínez, a, b Raquel Dacal Quintas, b Pedro Marcos Velázquez b

a Servicio de Neumología, Hospital Comarcal de Monforte de Lemos, Lugo, Spain
b Servicio de Neumología, Complexo Hospitalario Universitario de Ourense, Ourense, Spain

corresponding author.
E-mail address: marussantalla@gmail.com (M. Santalla Martínez).

Infections by Gram-Negative Bacilli in Patients With Pulmonary Arterial Hypertension Treated With Intravenous Prostacyclin

Infecciones por gramnegativos en pacientes con hipertensión arterial pulmonar tratados con prostaciclinas intravenosas

Dear Editor,

I have read with great interest the original article by López Medrano et al.1 regarding the high incidence of bacteremia due to Gram-negative bacteria (GNB) in patients with pulmonary arterial hypertension (PAH) treated with intravenous (IV) treprostinil compared with IV epoprostenol. This is a known finding in the literature and has been confirmed in a Spanish center with extensive experience in the management of PAH. They also suggest initial empirical therapeutic management until the pathogen is correctly identified. In their conclusions, the authors invite us to carefully weigh the risks and benefits of treatment with IV treprostinil.

Recently, Kitterman et al.2 have published data about the incidence of bloodstream infection in 1146 patients with PAH from the REVEAL Registry in the United States. They had been treated with either IV epoprostenol or treprostinil, and a greater incidence of infection due to GNB was found in the IV treprostinil group (0.20 vs 0.03 per 1000 days of treatment, P<.001). However, this US series shows that the rate of infection has dropped drastically in recent years since the publication and approval of the Clinical Practice Guidelines for the prevention of bacteremia due to central venous catheter in the treatment of PAH with prostanooids.3 Our own center had also experienced a reduction in the rates of infection in recent years since guidelines were adopted, at the correct level.